Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Heinzerling on Stage III Treatment of NSCLC

December 26th 2017

Josh H. Heinzerling, MD, Department of Radiation Oncology, Levine Cancer Institute, discusses the treatment of patients with stage III non-small cell lung cancer (NSCLC).

Expert Sheds Light on Lesser-Known Mutations in NSCLC

December 22nd 2017

Raghava R. Induru, MD, discusses lesser-known mutations in non-small cell lung cancer, such as TRK and BRAF.

Immunotherapy/RT Combos Could Be Next Wave of Novel Treatment in Lung Cancers

December 22nd 2017

Sagus Sampath, MD, discusses ongoing studies exploring checkpoint inhibitors with radiation therapy and the promise of integrating these 2 treatments in the field of non-small cell lung cancer.

Frontline Alectinib Approved in Europe for ALK-Positive NSCLC

December 22nd 2017

The European Commission has approved alectinib for the frontline treatment of patients with ALK-positive metastatic non–small cell lung cancer.

Dr. Sampath on Immunotherapy and Radiation Combinations in NSCLC

December 21st 2017

Sagus Sampath, MD, assistant professor, Department of Radiation Oncology, City of Hope, discusses combinations of immunotherapy and radiation for the treatment of patients with non-small cell lung cancer (NSCLC).

Immunotherapy and EGFR, ALK Inhibitors Deliver Precision Medicine in NSCLC

December 21st 2017

Edward S. Kim, MD, discusses the advancements in lung cancer in 2017, specifically in EGFR- and ALK-positive patients and those with PD-L1 expression.

Frontline Findings Put Fresh Focus on Immunotherapy in NSCLC

December 20th 2017

Findings from the phase III IMpower150 study have placed renewed focus on the optimal role for immunotherapy in the frontline setting for patients with advanced non

FDA Grants Frontline Osimertinib Priority Review for NSCLC

December 18th 2017

The FDA has granted a priority review to a supplemental new drug application for the use of osimertinib as a first-line treatment for patients with non–small cell lung cancer whose tumors harbor EGFR mutations.

Immunotherapy Emerges in Stage III NSCLC Treatment Landscape

December 17th 2017

John Heinzerling, MD, discusses the impact of durvalumab and other developments in the treatment of patients with stage III non-small cell lung cancer.

Dr. Gandara Discusses the OAK Trial for Lung Cancer

December 16th 2017

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, discussed the OAK study design for patients with lung cancer.

Deeper Understanding Emerging of KRAS Biology in NSCLC

December 16th 2017

Ferdinandos Skoulidis, MD, PhD, discusses potential treatment options for KRAS-mutated lung cancer and highlighted developments in biomarker research in other areas in the field.

Immunotherapy Resistance Remains a Puzzle

December 15th 2017

Checkpoint blockade immunotherapy has been hailed as a significant advance in anticancer treatment. Yet only a subset of patients experience long-term cancer remission as a result of these therapies, because a significant number of those who initially respond eventually develop resistance.

Dr. Mileham Discusses Biomarkers in Lung Cancer

December 14th 2017

Kathryn Mileham, MD, medical oncologist, Levine Cancer Institute, Carolinas HealthCare System, discusses biomarkers in lung cancer.

Frontline Atezolizumab Regimen Improves PFS in NSCLC

December 7th 2017

Treatment with the combination of atezolizumab, bevacizumab, carboplatin, and paclitaxel delayed progression or death by 38% compared with bevacizumab and chemotherapy alone for patients with advanced non-squamous non–small cell lung cancer.

Expert Discusses Developments in ALK/ROS1-Positive NSCLC

December 6th 2017

Vincent K. Lam, MD, discusses the treatment paradigm for patients with ALK/ROS1-translocated NSCLC.

Simon Says Immunotherapy Combo Regimens on Horizon in NSCLC

December 4th 2017

George R. Simon, MD, discusses the advancements being made with immunotherapy for the treatment of NSCLC.

Optimal Sequencing and Patient Selection Investigated in NSCLC

December 4th 2017

Frank E. Mott, MD, discusses optimal treatment selection strategies for patients with NSCLC.

Nivolumab Improves Survival in Pretreated Chinese NSCLC Patients

December 1st 2017

Nivolumab improved survival versus docetaxel in a predominantly Chinese population of patients with pretreated advanced or metastatic non-small cell lung cancer.

Dr. Kim on the Importance of Biomarker Testing for Lung Cancer

November 29th 2017

Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses the importance of biomarker testing in lung cancer.

Dr. Gainor Discusses the Future of EGFR+ NSCLC

November 28th 2017

Justin F. Gainor, MD, assistant professor of medicine, Harvard Medical School, attending physician, Massachusetts General Hospital, discusses the future of treatment for patients with EGFR-positive non-small cell lung cancer.